Neurochemistry: Molecular, Cellular and Medical Neurobiology

Below is a comprehensive, structured outline of Neurochemistry: Molecular, Cellular and Medical Neurobiology (up to 2026), under Chemistry, spanning 12 volumes. Each volume covers fundamental neurochemistry, molecular signaling, cellular neurobiology, neuropharmacology, neuroimmunology, metabolic pathways, neurodegenerative and psychiatric neurochemistry, developmental neurobiology, injury and repair, emerging technologies, and clinical translation.

Volume 1: Foundations of Neurochemistry – History, Molecules, and Methods

Part I: Defining Neurochemistry

Historical origins (Thudichum, 1884 – “chemical constitution of the brain”)
Relationship to neuroscience, molecular biology, and pharmacology
The neuron doctrine and chemical transmission (Loewi, Dale, Eccles)
Major milestones: identification of neurotransmitters, second messengers, receptors

Part II: The Chemical Composition of the Nervous System

Water, ions, and electrolytes
Amino acids, biogenic amines, neuropeptides
Lipids (phospholipids, sphingolipids, cholesterol, gangliosides)
Carbohydrates and glycoconjugates
Nucleic acids (DNA, RNA, non-coding RNAs)
Energy metabolites (ATP, phosphocreatine, lactate)

Part III: Basic Biochemical Principles

Protein structure and function (primary to quaternary, post-translational modifications)
Enzymology in neurochemistry (kinetics, regulation, cofactors)
Membrane biochemistry (lipid bilayers, membrane proteins, ion channels)
Thermodynamics and transport across the blood-brain barrier (BBB)

Part IV: Core Neurochemical Methods

Tissue homogenization, subcellular fractionation (synaptosomes, myelin, mitochondria)
Chromatography (HPLC, GC-MS, LC-MS/MS) for neurotransmitters and metabolites
Immunohistochemistry and immunofluorescence
In situ hybridization (ISH, RNAscope)
Western blotting and ELISA
Microdialysis and voltammetry (fast-scan cyclic voltammetry, FSCV)
Mass spectrometry imaging (MALDI-MSI, DESI)
Single-cell neurochemical profiling (patch-seq, scRNA-seq, scATAC-seq)

Part V: Model Systems in Neurochemistry

Primary neuronal and glial cultures
Brain slices (acute, organotypic)
Invertebrate models (Aplysia, Drosophila, C. elegans)
Rodent models (mouse, rat, transgenic/knockout lines)
Human iPSC-derived neurons and brain organoids
Emerging: 3D bioprinted neural tissues

Volume 2: Neurotransmitters and Neuromodulators – Synthesis, Storage, Release

Part I: Small Molecule Neurotransmitters

Glutamate – synthesis (glutaminase), vesicular transport (VGLUTs), recycling (EAATs)
GABA – synthesis (GAD65/67), vesicular transport (VGAT), catabolism (GABA-T)
Glycine – synthesis, transport (GlyT1/2), strychnine-sensitive receptors
Acetylcholine – synthesis (ChAT), vesicular transport (VAChT), degradation (AChE)
Dopamine – synthesis (tyrosine hydroxylase, DOPA decarboxylase), vesicular transport (VMAT2), catabolism (MAO, COMT)
Norepinephrine – synthesis (dopamine β-hydroxylase), vesicular transport
Epinephrine – synthesis (PNMT), adrenal vs. brain
Serotonin (5-HT) – synthesis (tryptophan hydroxylase 1/2, aromatic L-amino acid decarboxylase), vesicular transport (VMAT2)
Histamine – synthesis (histidine decarboxylase), HDC knockout phenotypes

Part II: Neuropeptides

Biosynthesis (prepropeptide → propeptide → active peptide)
Peptide processing enzymes (prohormone convertases PC1/3, PC2, carboxypeptidase E)
Major families:
Opioid peptides (β-endorphin, enkephalins, dynorphins)
Tachykinins (substance P, neurokinin A/B)
Neurohypophyseal hormones (vasopressin, oxytocin)
Hypothalamic releasing hormones (CRH, TRH, GnRH, GHRH, somatostatin)
Neuropeptide Y (NPY)
Galanin, orexin/hypocretin, melanin-concentrating hormone (MCH)
Corticotropin-releasing factor (CRF)
Brain-derived neurotrophic factor (BDNF) and other neurotrophins
Co-transmission (neuropeptide + small molecule)

Part III: Gaseous and Unconventional Transmitters

Nitric oxide (NO) – synthesis (nNOS, eNOS, iNOS), targets (guanylyl cyclase), role in synaptic plasticity
Carbon monoxide (CO) – heme oxygenase (HO-1, HO-2)
Hydrogen sulfide (H₂S) – CBS, CSE, MPST
Endocannabinoids – anandamide (AEA), 2-arachidonoylglycerol (2-AG), synthesis (NAPE-PLD, DAGL), degradation (FAAH, MAGL)

Part IV: Vesicular Release Machinery

Synaptic vesicle cycle (SV2, synaptotagmin, synapsin, synaptobrevin/VAMP)
SNARE complex (syntaxin, SNAP-25, VAMP)
Calcium-triggered fusion (synaptotagmin as Ca²⁺ sensor)
Kiss-and-run vs. full fusion
Quantal release and quantal analysis (del Castillo & Katz)

Volume 3: Receptors, Ion Channels, and Signal Transduction

Part I: Ligand-Gated Ion Channels (Ionotropic Receptors)

Glutamate receptors – AMPA (GluA1-4), kainate (GluK1-5), NMDA (GluN1, GluN2A-D, GluN3A-B)
NMDA receptor co-agonists (glutamate + glycine/D-serine), Mg²⁺ block, Ca²⁺ permeability
GABA-A receptors – subunit composition (α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3), benzodiazepine and barbiturate binding sites
Glycine receptors (α1-4, β) – strychnine antagonism
Nicotinic acetylcholine receptors (α2-10, β2-4) – homomeric vs. heteromeric
Serotonin 5-HT3 receptor – cation channel
P2X receptors (ATP-gated, P2X1-7)
Zinc-activated channels (ZAC)

Part II: G Protein-Coupled Receptors (GPCRs)

GPCR superfamily structure (7-transmembrane domains)
G protein subunits (Gαs, Gαi/o, Gαq/11, Gα12/13) – effectors (adenylyl cyclase, PLC, ion channels)
Specific GPCRs by neurotransmitter:
Dopamine (D1-like: D1, D5; D2-like: D2, D3, D4)
Norepinephrine (α1A/B/D, α2A/B/C, β1-3)
Serotonin (5-HT1A/B/D/E/F, 5-HT2A/B/C, 5-HT4, 5-HT5A/B, 5-HT6, 5-HT7)
Acetylcholine (muscarinic M1-M5)
GABA-B (GABA-B1, GABA-B2)
Glutamate (mGluR1-8, groups I/II/III)
Opioid (μ, δ, κ, nociceptin/orphanin FQ)
Cannabinoid (CB1, CB2)
Adenosine (A1, A2A, A2B, A3)
Histamine (H1-H4)
Neuropeptide receptors (NPY Y1-5, CRF1/2, orexin OX1/2, etc.)

Part III: Receptor Regulation and Trafficking

Desensitization (homologous vs. heterologous)
β-arrestin pathways (G protein-independent signaling)
Endocytosis (clathrin, caveolin) and recycling
Ubiquitination and lysosomal degradation

Part IV: Second Messenger Systems

cAMP/PKA pathway – adenylyl cyclase isoforms, phosphodiesterases (PDEs), CREB
Phosphoinositide (PI) pathway – PLCβ, IP3, DAG, PKC, Ca²⁺ release
Calcium signaling – intracellular stores (ER), calmodulin (CaM), CaMKII, calcineurin
MAPK/ERK pathway (Ras/Raf/MEK/ERK) – role in plasticity and growth
PI3K/Akt/mTOR pathway – cell survival, translation
Nitric oxide/cGMP/PKG pathway

Part V: Ion Channels (Voltage-Gated and Others)

Voltage-gated sodium channels (Nav1.1-1.9) – structure, inactivation, toxin binding (tetrodotoxin, saxitoxin)
Voltage-gated calcium channels (Cav1.x L-type, Cav2.x P/Q/N/R-type, Cav3.x T-type)
Voltage-gated potassium channels (Kv1-12) – delayed rectifier, A-type, M-current
Inward rectifier potassium channels (Kir) – GIRK channels
Two-pore domain potassium channels (K2P) – leak channels
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels – Iₕ current
Transient receptor potential (TRP) channels (TRPV1-4, TRPM1-8, TRPC1-7, TRPA1, TRPML, TRPP) – thermosensation, mechanosensation, chemosensation

Volume 4: Cellular Neurobiology – Neurons, Glia, and Synaptic Plasticity

Part I: Neuronal Structure and Compartments

Axonal transport (kinesin anterograde, dynein retrograde) – fast and slow components
Dendritic spines – morphology, plasticity, spine apparatus
Axon initial segment (AIS) – ion channel clustering, action potential initiation
Presynaptic terminal – active zone, reserve pool, recycling pool

Part II: Glial Neurochemistry

Astrocytes – glutamate uptake (EAAT1/2), glutamine synthetase, glycogen storage, lactate shuttle (ANLS), K⁺ buffering, gliotransmission (ATP, D-serine, glutamate)
Oligodendrocytes – myelin synthesis (MBP, PLP, MAG, MOG), cholesterol and lipid metabolism, activity-dependent myelination
Microglia – immune surveillance, cytokine release (IL-1β, TNF-α, IL-6), phagocytosis, TREM2, CX3CR1, P2Y12 receptors
NG2 glia (polydendrocytes) – proliferation, differentiation into oligodendrocytes
Ependymal cells – CSF secretion (choroid plexus)

Part III: Synaptic Transmission and Plasticity

Quantal release and the Katz model
Short-term plasticity (facilitation, augmentation, potentiation, depression)
Long-term potentiation (LTP) – NMDA-dependent (CA1), mossy fiber (cAMP-dependent), timing-dependent (STDP)
Long-term depression (LTD) – metabotropic glutamate receptor-dependent (cerebellum, hippocampus)
Homeostatic plasticity (synaptic scaling) – TNF-α, Arc, retinoic acid
Spike-timing-dependent plasticity (STDP) – Hebbian and anti-Hebbian windows

Part IV: Metabolism and Energetics

Brain energy consumption (20% of body’s O₂ at 2% mass)
Glucose metabolism – glycolysis, TCA cycle, oxidative phosphorylation
Ketone bodies as alternative fuel (ketogenic diet mechanisms)
Lactate shuttle (astrocyte–neuron) – controversy and evidence
Creatine kinase system
Hypoxia and energy failure (ischemic cascade)

Volume 5: Neurochemistry of Development and Aging

Part I: Neural Development – Molecular Mechanisms

Neural induction (BMP inhibition, noggin, chordin, follistatin)
Neurogenesis (Ngn1/2, Ascl1, NeuroD) – embryonic and adult (subventricular zone, dentate gyrus)
Neuronal migration (reelin, Dab1, Cdk5, Lis1, doublecortin)
Axon guidance – netrin/DCC, slit/robo, semaphorin/neuropilin/plexin, ephrin/Eph
Synaptogenesis – neurexin/neuroligin, LRRTMs, cerebellin/GluD2
Programmed cell death – caspases, Bcl-2 family, neurotrophin dependence (NGF, BDNF, NT-3, NT-4)
Myelination (developmental timeline, growth factors: PDGF, FGF, IGF-1)

Part II: Neurotrophins and Growth Factors

NGF – TrkA, p75NTR, retrograde signaling
BDNF – TrkB, proBDNF, role in LTP and depression
NT-3 – TrkC
NT-4 – TrkB
GDNF family (GDNF, neurturin, artemin, persephin) – Ret/GFRα receptors
CNTF, LIF, cardiotrophin-1 – gp130 signaling

Part III: Adult Neurogenesis

Neurogenic niches (SVGZ, SGZ)
Molecular regulation (Wnt, Notch, Shh, BMP)
Environmental influences (exercise, enrichment, stress, antidepressants)
Functional roles in olfaction, memory, and mood

Part IV: Aging Neurochemistry

Oxidative stress – reactive oxygen species (ROS), superoxide dismutase (SOD), catalase, glutathione peroxidase, mitochondrial dysfunction
Protein aggregation – tau, α-synuclein, Aβ, TDP-43, huntingtin
Decline in neurotransmitter systems (dopamine in substantia nigra, acetylcholine in basal forebrain)
Calcium dysregulation hypothesis of aging
Senescence (p16INK4a, p21, SASP) in glia
Sirtuins (SIRT1-7) and NAD⁺ metabolism in brain aging
Autophagy decline and mitophagy

Volume 6: Neurochemistry of Neurodegenerative Diseases

Part I: Alzheimer’s Disease (AD)

Amyloid precursor protein (APP) processing – α-, β-, γ-secretases
Aβ peptides (Aβ40, Aβ42) – oligomers, fibrils, plaques
Tau protein – phosphorylation (GSK3β, CDK5, MARK), aggregation, neurofibrillary tangles
APOE4 isoform – lipid transport, microglial function
Neuroinflammation in AD – TREM2, complement, NLRP3 inflammasome
Biomarkers – CSF Aβ42/p-tau/t-tau, plasma p-tau217, amyloid/tau PET
Metabolic dysfunction – glucose hypometabolism (FDG-PET), mitochondrial defects

Part II: Parkinson’s Disease (PD)

Dopamine neuron loss in substantia nigra pars compacta
α-Synuclein (SNCA) – Lewy bodies, oligomers, prion-like spreading
Parkin (PARK2), PINK1, DJ-1, LRRK2, GBA mutations – mitochondrial and lysosomal pathways
Oxidative stress and iron accumulation (ferroptosis)
Neuromelanin
Biomarkers – α-synuclein seeding amplification assay (SAA) from CSF
Gut-brain axis and vagal spread hypothesis

Part III: Huntington’s Disease (HD)

CAG repeat expansion in huntingtin (HTT) – polyglutamine tract
Mutant huntingtin aggregation (nuclear and cytoplasmic)
Transcriptional dysregulation (Sp1, CREB, PGC-1α)
Striatal medium spiny neuron vulnerability
Metabolic deficits and mitochondrial dysfunction

Part IV: Amyotrophic Lateral Sclerosis (ALS)

SOD1 mutations – oxidative damage, protein aggregation
TDP-43 pathology (cytoplasmic inclusions, loss of nuclear function)
C9orf72 hexanucleotide repeat expansion – dipeptide repeat proteins (DPRs), gain-of-function
FUS, TBK1, OPTN, VCP, UBQLN2 mutations
Glial contributions (astrocyte and microglial toxicity to motor neurons)

Part V: Prion Diseases

Prion protein (PrPᶜ) to scrapie isoform (PrPˢᶜ) conversion
Strain phenomena and species barriers
Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker (GSS), fatal familial insomnia (FFI)

Part VI: Other Neurodegenerative Disorders

Frontotemporal dementia (FTD) – tau (MAPT), progranulin (GRN), C9orf72
Lewy body dementia (DLB)
Multiple system atrophy (MSA) – glial cytoplasmic inclusions (α-synuclein)
Progressive supranuclear palsy (PSP) – tau (4R)
Corticobasal degeneration (CBD)

Volume 7: Neurochemistry of Psychiatric Disorders

Part I: Schizophrenia

Dopamine hypothesis (hyperdopaminergia in striatum, hypodopaminergia in prefrontal cortex)
Glutamate hypothesis (NMDA receptor hypofunction – ketamine/PCP model)
GABAergic interneuron deficits (parvalbumin-positive, somatostatin-positive)
Myelin and oligodendrocyte abnormalities
kynurenine pathway metabolites (quinolinic acid, kynurenic acid)
Antipsychotic mechanisms – D2 antagonism, 5-HT2A antagonism, partial agonism

Part II: Major Depressive Disorder (MDD)

Monoamine hypotheses (serotonin, norepinephrine, dopamine) – limitations
Neurotrophic hypothesis (BDNF, TrkB, VEGF)
Glutamate hypothesis (ketamine’s rapid antidepressant effect via NMDA antagonism)
GABAergic deficits
HPA axis hyperactivity (CRH, cortisol, GR resistance)
Inflammatory hypothesis (IL-6, TNF-α, CRP, IDO activation, tryptophan depletion)
Metabolic and mitochondrial dysfunction

Part III: Bipolar Disorder

Mania and depression neurochemistry – dopamine, norepinephrine, GABA, glutamate
Lithium’s mechanisms – inositol depletion (IMPA), GSK3β inhibition, neuroprotection
Valproate and lamotrigine – effects on sodium channels, GABA

Part IV: Anxiety and PTSD

GABA/glutamate balance in amygdala and prefrontal cortex
Serotonin (5-HT1A, 5-HT2A, 5-HT3)
Neuropeptide Y (NPY) – anxiolytic
CRH – anxiogenic
Endocannabinoid system (anandamide, 2-AG) – stress buffering

Part V: Substance Use Disorders

Mesolimbic dopamine pathway (VTA → NAc) – reward
Drugs of abuse mechanisms:
Cocaine (DAT blockade)
Amphetamines (reverse DAT transport)
Opioids (μ receptor activation, disinhibition of VTA dopamine neurons)
Nicotine (α4β2 nAChR activation)
Alcohol (GABA-A positive allosteric modulation, NMDA antagonism)
Cannabis (CB1 receptor activation)
Neuroadaptations – ΔFosB, CREB, dynorphin, glutamate plasticity
Withdrawal and negative affect (CRH, noradrenaline)

Volume 8: Neurochemistry of Pain, Sleep, and Circadian Rhythms

Part I: Pain Neurochemistry

Nociceptor transduction – TRPV1 (capsaicin, heat), TRPA1 (mustard oil, cold), ASICs, P2X3
Peripheral sensitization – bradykinin, prostaglandins (COX), NGF, CGRP, substance P
Spinal cord transmission – glutamate (NMDA, AMPA), substance P (NK1), BDNF
Central sensitization – wind-up, PKCγ, ERK
Descending modulation – periaqueductal gray (PAG), rostral ventromedial medulla (RVM)
Opioidergic (β-endorphin, enkephalin, dynorphin)
Serotonergic (5-HT1A, 5-HT3)
Noradrenergic (α2 receptors)
Chronic pain – microglial activation (P2X4, BDNF), astrocytic changes

Part II: Sleep Neurochemistry

Wake-promoting systems – orexin/hypocretin (lateral hypothalamus), histamine (TMN), dopamine (VTA), norepinephrine (LC), acetylcholine (basal forebrain, PPT/LDT)
NREM sleep – VLPO (GABA, galanin) inhibition of wake systems, adenosine (A1, A2A receptors)
REM sleep – acetylcholine (PPT/LDT), GABA (vPAG, lateral LPT), glutamate
Melatonin – pineal gland synthesis (AANAT, ASMT), MT1/MT2 receptors, circadian entrainment
Homeostatic sleep drive – adenosine, prostaglandin D2, nitric oxide

Part III: Circadian Rhythms

Suprachiasmatic nucleus (SCN) molecular clock – transcription-translation feedback loops
Core loop: CLOCK/BMAL1 → Per (1-3) and Cry (1-2) → repression
Stabilizing loops: REV-ERBα/β, RORα
Photon input – melanopsin (ipRGCs) → retinohypothalamic tract → SCN
Outputs – rhythmic expression of clock-controlled genes (Dbp, Tef, Hlf, Wee1)
Peripheral clocks (liver, heart, adipose) and brain clocks
Chronotype and chronodisruption (shift work, jet lag)

Volume 9: Neuroimmunology and Neuroinflammation

Part I: Immune Cells in the CNS

Microglia – origin (yolk sac), self-renewal, morphology, markers (IBA1, P2RY12, TMEM119, CX3CR1)
Border-associated macrophages (BAMs) – meningeal, perivascular, choroid plexus
Astrocytes – reactive astrogliosis (GFAP↑, vimentin↑, nestin↑), A1 (neurotoxic) vs. A2 (neuroprotective) phenotypes
Infiltrating T cells, B cells, monocytes (in pathology)

Part II: Inflammatory Mediators

Cytokines – IL-1β, IL-6, TNF-α, IL-10, TGF-β
Chemokines – CCL2, CXCL10, CX3CL1 (fractalkine)
Complement system – C1q, C3, C5, membrane attack complex (MAC)
Prostaglandins (COX-1/2, PGE₂, PGD₂)
Reactive oxygen and nitrogen species (NOX2, iNOS, MPO)

Part III: Neuroimmune Signaling Pathways

Toll-like receptors (TLR2, TLR3, TLR4, TLR7, TLR9) – ligands (LPS, dsRNA, ssRNA, CpG DNA)
NLRP3 inflammasome – activation (ATP, Aβ, α-synuclein, urate), caspase-1, IL-1β/IL-18
NF-κB pathway in glia
JAK/STAT pathway (IFN-γ, IL-6)

Part IV: Neuroimmune Disorders

Multiple sclerosis (MS) – oligodendrocyte damage, demyelination, Th17 cells, B cells, oligoclonal bands
Autoimmune encephalitis (anti-NMDA receptor, anti-LGI1, anti-GAD65)
Neuromyelitis optica (NMO) – aquaporin-4 autoantibodies
Microgliopathies (ALSP due to CSF1R mutations, Nasu-Hakola due to TREM2/DAP12)

Part V: Neuroinflammation in Disease

Alzheimer’s – microglial TREM2, CD33, CR1, complement, NLRP3
Parkinson’s – microglial activation, MHC-II upregulation, α-synuclein as DAMP
Depression – microglial priming, kynurenine pathway, sickness behavior
Traumatic brain injury (TBI) – diffuse axonal injury, chronic traumatic encephalopathy (CTE)

Volume 10: Neurochemistry of Injury, Repair, and Regeneration

Part I: Acute Neural Injury

Ischemic stroke – excitotoxicity (glutamate, NMDA), calcium overload, mitochondrial permeability transition (mPT), ROS, inflammation, apoptosis (caspase-3)
Traumatic brain injury (TBI) – mechanical damage, diffuse axonal injury (β-APP accumulation), hemorrhage, edema
Spinal cord injury (SCI) – primary and secondary injury, glial scar (chondroitin sulfate proteoglycans, CSPGs), myelin-associated inhibitors (Nogo-A, MAG, OMgp)

Part II: Axonal and Synaptic Degeneration

Wallerian degeneration – SARM1 (NAD⁺ depletion), NMNAT2 protection
Axonal transport defects – dynein/kinesin mutations, tauopathies
Synaptic loss mechanisms – complement (C1q, C3) tagging, microglial pruning

Part III: Repair and Regeneration Mechanisms

Growth cone collapse vs. regeneration – RhoA/ROCK pathway
Intrinsic growth capacity – PTEN/mTOR, KLF family, SOCS3
Neurotrophic support after injury (BDNF, GDNF, NGF, CNTF)
Oligodendrocyte precursor cell (OPC) response to demyelination – differentiation failure in MS
Stem cell niches in repair (SVZ, SGZ) – limited migration to injury sites

Part IV: Glial Scar and CSPGs

Chondroitin sulfate proteoglycans (aggrecan, brevican, neurocan, versican)
Chondroitinase ABC as therapeutic
Astrocyte reactivity – GFAP, vimentin, nestin, STAT3 pathway

Part V: Biomaterials and Molecular Therapies

Hydrogels for SCI repair (peptide amphiphiles, hyaluronic acid, Matrigel)
Growth factor delivery (heparin-binding, slow-release microspheres)
Gene therapy for regeneration (AAV-PTEN shRNA, AAV-SOCS3)
CRISPR editing in injury models

Volume 11: Emerging Technologies and Molecular Tools (2020–2026)

Part I: Optogenetics and Chemogenetics

Optogenetic actuators – channelrhodopsins (ChR2, ChRmine, ChroME), halorhodopsin (NpHR), archaerhodopsin (Arch)
Genetically encoded voltage indicators (GEVIs) – ArcLight, ASAP, Voltron
Chemogenetics – DREADDs (hM3Dq, hM4Di, KORD, rM3Ds)
Designer receptors and their ligands (clozapine-N-oxide, deschloroclozapine)

Part II: Genetically Encoded Biosensors

Calcium indicators – GCaMP6, GCaMP7, GCaMP8 (fast kinetics), jGCaMP7
Neurotransmitter sensors – GRAB sensors (dopamine, serotonin, norepinephrine, acetylcholine, adenosine), iGluSnFR, GABA-sensor, dLight
Voltage sensors – ASAP, Voltron
Metabolic sensors – ATP (ATeam, PercevalHR), lactate (Laconic), NADH (Peredox)

Part III: Proteomics and Metabolomics

Quantitative proteomics (SILAC, TMT, LFQ) in synaptosomes, myelin, CSF
Spatial proteomics (Deep Visual Proteomics, GeoMX)
Metabolomics (LC-MS/MS, NMR) – neurotransmitter turnover, energy metabolites, lipidomics
Post-translational modification mapping (phosphoproteomics, ubiquitinomics, acetylation)

Part IV: Single-Cell and Spatial Omics

Single-cell RNA-seq (10x Genomics, SMART-seq) – neuronal subtypes, glial heterogeneity
Single-nucleus RNA-seq (snRNA-seq) – archived human brain tissue
Spatial transcriptomics (Visium, MERFISH, Xenium, CosMX)
Single-cell ATAC-seq – chromatin accessibility in brain cells
Multi-omics (RNA + protein, RNA + ATAC)

Part V: CRISPR and Gene Editing

CRISPR-Cas9, Cas12, Cas13 (RNA editing)
Base editing (ABE, CBE) – correction of point mutations
Prime editing – versatile DNA editing
Epigenome editing (CRISPRa, CRISPRi, dCas9-p300, dCas9-KRAB)
In vivo delivery – AAV, LNP, virus-like particles (VLPs)

Part VI: Brain Organoids and Assembloids

Cerebral organoids (Lancaster & Knoblich, 2013 – 2026 refinements)
Region-specific organoids (midbrain, striatum, cerebellum, hippocampus)
Vascularized organoids
Assembloids (cortex–striatum, cortex–spinal cord, thalamus–cortex)
Microelectrode array integration (MEA) for functional characterization

Part VII: In Vivo Neurochemistry

Fiber photometry (GCaMP, GRAB sensors) – freely behaving animals
Two-photon imaging with biosensors
Fast-scan cyclic voltammetry (FSCV) with carbon-fiber electrodes
Microdialysis coupled to LC-MS
GRAB sensors in mice and rats (2020–2025 expansion)

Volume 12: Translational Neurochemistry – Diagnostics, Therapeutics, and Future Directions

Part I: Neurochemical Biomarkers

CSF biomarkers – Aβ42/40, p-tau181/217, t-tau (AD), neurofilament light (NfL) for neurodegeneration, glial fibrillary acidic protein (GFAP) for astrogliosis
Blood biomarkers – plasma p-tau217, NfL, GFAP, exosomal α-synuclein
Urine and saliva neurochemical markers (limited utility)
PET tracers – amyloid (PiB, Florbetapir, Flutemetamol), tau (Flortaucipir, MK-6240), neuroinflammation (TSPO tracers: PBR28, DPA-714), dopamine (FDOPA, D2 receptor tracers)

Part II: Neurochemical Pharmacotherapy

Alzheimer’s – cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine (NMDA antagonist), aducanumab/lecanemab (anti-Aβ antibodies, 2021–2023 approvals)
Parkinson’s – L-DOPA (aromatic amino acid decarboxylase with carbidopa), MAO-B inhibitors (selegiline, rasagiline), COMT inhibitors (entacapone), dopamine agonists (pramipexole, ropinirole), amantadine
Depression – SSRIs (fluoxetine, sertraline), SNRIs (venlafaxine, duloxetine), ketamine/esketamine (2020–2026 expanded use), psilocybin (Phase III trials by 2026)
Schizophrenia – dopamine D2 antagonists (haloperidol, risperidone, paliperidone), partial agonists (aripiprazole, brexpiprazole, cariprazine), M1/M4 muscarinic agonists (emraclidine – Phase III 2024–2026)
Epilepsy – sodium channel blockers, GABAergic agents, SV2A modulators
Multiple sclerosis – immunomodulators (interferon-β, glatiramer acetate, anti-CD20 mAbs, S1P modulators)

Part III: Gene and Cell Therapies

AAV gene therapy – spinal muscular atrophy (Zolgensma – SMN1), AADC deficiency, giant axonal neuropathy, RPE65 deficiency
Antisense oligonucleotides (ASOs) – nusinersen (SMA), tofersen (SOD1 ALS, 2023 accelerated approval)
CRISPR therapies (in trials for Huntington’s, Leber congenital amaurosis by 2026)
Induced pluripotent stem cell (iPSC) derived neurons for cell replacement (PD – dopamine neurons, phase I/II trials 2020–2026)

Part IV: Neurometabolic and Mitochondrial Disorders

Mitochondrial diseases – Leigh syndrome, MELAS, MERRF, LHON
Lysosomal storage disorders – Gaucher (glucocerebrosidase), Tay-Sachs (HexA), Niemann-Pick (NPC1), enzyme replacement therapy (ERT) and substrate reduction therapy (SRT)
Peroxisomal disorders – adrenoleukodystrophy (ALD), Zellweger spectrum

Part V: Neurotoxicology

Heavy metals – lead (Pb²⁺), mercury (MeHg), manganese (Mn²⁺)
Pesticides – paraquat, rotenone (mitochondrial toxins, PD risk)
Drugs of abuse neurotoxicity – methamphetamine, MDMA, alcohol (Wernicke–Korsakoff – thiamine deficiency)
Chemotherapy-induced cognitive impairment (“chemobrain”) – oxidative stress, microglial activation
Anesthetics – neurotoxicity in developing brain (GABA-A, NMDA)

Part VI: Future Directions (2026 and beyond)

In vivo real-time neurotransmitter mapping (next-gen GRAB sensors, voltage imaging)
Whole-brain molecular mapping (spatial omics at cellular resolution)
Closed-loop neurochemical modulation (optogenetics + biosensor feedback)
Digital neurochemistry – AI-predicted neurochemical dynamics
Personalized neurochemistry – polygenic risk scores + metabolomics for psychiatric drug selection
Brain-machine interfaces (BMI) with neurochemical sensing (e.g., dopamine-based BMI for paralysis)

Spesialised Topics

Disease
Psychology
Mental Disorder
Psychiatry
Neuropharmacology
Clinical Neuroscience and Neurological Disorders
Glial Biology
Neuroimmunology
Computational Neuroscience
Key discoveries: first neurotransmitter isolation, receptor cloning, optogenetics, CRISPR
FDA approvals: L-DOPA, SSRIs, anti-Aβ antibodies, gene therapies

Appendixes (across all volumes)

Glossary of neurochemical terms (500+ definitions)
Neurotransmitter synthesis pathways (full metabolic diagrams)
Receptor and ion channel tables (subunits, localization, agonists, antagonists, effectors)
Neurochemical methods reference (principles, strengths, limitations of each technique)
Commonly used neurochemical reagents and their targets (pharmacology tables)
Brain region–specific neurochemical profiles (neurotransmitter and receptor densities)
CSF and blood biomarker reference ranges for neurodegenerative diseases
Neurochemical animal models (transgenic lines, toxin models, viral vector tools)
Timeline of major neurochemistry discoveries (1884–2026)
Safety and ethics in human neurochemical research (in vivo microdialysis, biomarker studies, genetic testing)
Neurochemical databases and resources (Human Protein Atlas, BrainMap, Allen Brain Atlas, Gene Ontology)
Index (cross-referenced by molecule, pathway, disease, technique, and volume)